Daval International Ltd. Is conducting an open label study in the United Kingdom which will examine the benefits of AIMSPRO, a novel therapy intended to treat those suffering with Amyotrophic lateral sclerosis (ALS) - also known as Lou Gehrig’s disease or Motor Neurones Disease.
Daval International is seeking ALS patients aged 18 years or older who fit their study criteria to participate for a minimum of 6 months.
If you or someone you know would like to find out more about being included in this study, please message me.